A vital asset of the MRC-PPU is the Division of Signal Transduction Therapy (DSTT). This division operates as a unique collaboration between world leading pharmaceutical companies and scientists in the MRC-PPU and signalling researchers at the University of Dundee’s School of Life Sciences. …more

The MRC Protein Phosphorylation and Ubiquitylation Unit has initiated a search for a new PI working in the area of protein phosphorylation and/or ubiquitylation. …more

Our eighth MRC PPU alumni interview is with Alberto Vitari, ex-PhD student who was supervised by Dario Alessi. …more

We are seeking to appoint a highly motivated and experienced scientist with considerable expertise in mass spectrometry to take charge of running major research collaborative projects with the group leaders in the MRC PPU. …more

Dr Sambit Nanda has been awarded a research grant of £15,000 from Tenovus, Scotland to continue his exciting new research on inflammasomes. …more

Embryonic Stem Cells (ESCs) have the potential to provide tissue replacement therapies for a number of debilitating diseases. This is because ESCs have the capacity to differentiate into any cell type in the adult body, a property known as pluripotency. …more

Mitochondria are the essential energy-generating powerhouses that provide our cells with the energy of life. However, their malfunction has a dark side. …more

Our seventh MRC PPU alumni interview is with Elton Zeqiraj, ex-PhD student who was jointly supervised by Dario Alessi and Daan van Aalten. …more

PI3K and Akt inhibitors are being evaluated in clinical trials for the treatment of human tumours including breast cancer that display driver mutations that inappropriately elevate the PI3K/Akt signalling pathway. Despite initial promise, the majority of these tumours rapidly evolve to resist the PI3K/Akt pathway therapy.  …more

Work in the Alessi lab in the MRC PPU has been geared towards understanding how mutations in LRRK2 impair its biological functions and cause Parkinson’s. …more